A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 341
Last updated 2021-05-06
Summary
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Conditions
Interventions
- DRUG
- DRUG
- DRUG
-
Pemetrexed
- OTHER
-
Best Supportive Care
Palliative radiation, palliative surgery and/or other best supportive care treatments
- DRUG
- DRUG
- DRUG
- DRUG
- DRUG
-
Erlotinib
- DRUG
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-23
- Primary Completion
- 2020-04-15
- Completion
- 2020-04-15
Countries
- United States
Study Locations
More Related Trials
-
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
NCT03527108 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
NCT02350764 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks
NCT02713867 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
NCT02538666 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
NCT01454102 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)
NCT03353675 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
NCT02967133 ·Status: TERMINATED ·Phase: PHASE2
-
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
NCT02869789 ·Status: COMPLETED ·Phase: PHASE4
-
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
NCT03041181 ·Status: TERMINATED ·Phase: PHASE2
-
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
NCT04507906 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC
NCT04023617 ·Status: UNKNOWN ·Phase: PHASE2
-
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
NCT04475939 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
NCT04025879 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02477826 ·Status: COMPLETED ·Phase: PHASE3
-
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen
NCT02066636 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
NCT07024862 ·Status: ACTIVE_NOT_RECRUITING
-
Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer
NCT02659059 ·Status: COMPLETED ·Phase: PHASE2
-
A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
NCT04015778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
NCT03215706 ·Status: COMPLETED ·Phase: PHASE3
-
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
NCT02846792 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy
NCT04151563 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer
NCT03121417 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer
NCT03048136 ·Status: WITHDRAWN ·Phase: PHASE3
-
Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC
NCT03573947 ·Status: COMPLETED ·Phase: PHASE2